波萨可纳醇纳米晶体固体分散的开发:制备,表征和体内评估
Ranga Goud Rayapolu1,2, Balvant Yadav2, Shashank S Apte2
1Birla Institute of Technology and Science (BITS) Pilani, Hyderabad Campus, Shameerpet, Hyderabad, Telangana, India.
Pharmaceutical development and technology
|May 7, 2024
概括
这项研究开发了一种新型纳米晶体固体分散 (NCS) 的波萨可纳 (PCZ) 来增强口服生物可用性. 优化的PCZ-NCS配方显著改善了大鼠的药物溶解性,溶解和药物动力学参数.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 纳米技术 纳米技术
背景情况:
- 波萨可纳 (PCZ) 是一种重要的抗真菌剂.
- 它的有效性受到水溶性差和口服生物可用性低 (BCS II类药物) 的限制.
- 现有的配方努力克服这些局限性.
研究的目的:
- 为了增强口服波萨可纳 (PCZ) 的生物可用性.
- 开发和描述一种新的纳米晶体固体分散 (NCS) 配方PCZ.
- 评估开发的NCS的体外和体内表现.
主要方法:
- 使用降水和高压均质化制备PCZ-NCS,随后进行冷干燥.
- 各种表面活性剂和聚合物被选为最佳颗粒大小和稳定性.
- 鉴定包括颗粒大小分析,SEM,DSC,XRD,可溶性研究,溶解测试和大鼠的药物动力学评估.
主要成果:
- 优化的PCZ-NCS配方 (0.2%Eudragit S100,0.2%SLS) 实现了平均颗粒大小为73.31 nm.
- 纳米化使PCZ和溶解度增加了18倍.
- 在体内研究显示,与市场上市的配方相比,Cmax增加了2.58倍,AUCtotal增加了2.64倍.
结论:
- 开发的PCZ-NCS配方显著提高了posaconazole的口服生物可用性.
- 这种纳米晶体方法为改善难溶性药物的输送提供了一个有希望的策略.
- PCZ-NCS代表了改善抗真菌治疗的可行替代方案.
相关概念视频
Factors Affecting Dissolution: Particle Size and Effective Surface Area
818
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
818
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
301
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
301
Factors Influencing Drug Absorption: Drug Dissolution
468
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
468
Factors Influencing Drug Absorption: Pharmaceutical Parameters
133
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
133
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
200
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
200


